Pfizer announced the failure of its Phase 3 trial for inclacumab, a sickle cell disease candidate acquired through its $5.4 billion deal for Global Blood Therapeutics. The investigational drug did not significantly reduce vaso-occlusive crises compared to placebo. This trial failure follows Pfizer’s earlier voluntary withdrawal of Oxbryta due to safety concerns related to higher complication and mortality rates. The disappointing data cast uncertainties on Pfizer's portfolio strategy for sickle cell therapeutics and R&D efforts in hematology.